Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Why Proofpoint Stock Rose 40% in the Last Month

By Chris Lau, InvestorPlace Contributor

Proofpoint stock rose sharply ahead of and after its Q4 earnings report. Why is this software security stock up?

3 Biotech Stocks That Pay Solid Dividends

By Chris Lau, InvestorPlace Contributor

Biotech stocks offer more than just capital gains; some of them pay dividends. Here are three dividend-paying biotechs to consider.

What to Do After Pyxus International Stock Rallied by Over 25%

By Chris Lau, InvestorPlace Contributor

Pyxus stock rallied by over 25% on no news. Are speculators betting on a strong upcoming earnings report from PYX?

QCOM’s Future Will Not Be Revealed With Tomorrow’s Earnings

By Chris Lau, InvestorPlace Contributor

QCOM reports quarterly earnings Wednesday after the close, but the FTC case against Qualcomm will be what dictates the stock's next move.

7 Semiconductor Stocks to Buy Now 

By Chris Lau, InvestorPlace Contributor

Thanks to strong earnings reports, semiconductor stocks are already rallying, after weeks of underperformance and fear. What do you buy now?

Where Will Apple Stock Be Trading in a Year?

By Chris Lau, InvestorPlace Contributor

Apple shares are down on lower iPhone unit sales, while service revenues continue to break new record levels. What's next for AAPL stock?

All Signals Are Positive for Buying Abbott Laboratories

By Chris Lau, InvestorPlace Contributor

Abbott is about to report another quarter to cap 2018's strong annual performance. ABT stock also offers a dividend for income investors.

Here’s Why Markets Are Willing To Value Teleflex Stock At A Premium

By Chris Lau, InvestorPlace Contributor

Four analysts covering Teleflex have a $310 target on the shares; that's 20% upside from the current TFX stock price.

With Trial Results Due, This Could Be a Breakout Year for Cara Stock

By Chris Lau, InvestorPlace Contributor

Putting in the work may pay off big for In 2018, setting up the clinical studies dominated Cara Therapeutics' activities. For 2019, the study results may drive Cara stock higher. stock

UnitedHealth Is a Steady Investment for the Patient Investor

By Chris Lau, InvestorPlace Contributor

UnitedHealth rose after reporting impressive quarterly results. Gains in UNH stock may not stop there as investors embrace the growth story.

Load More